AUS
NZ
UK
CA
USA
IND
Telo Genomics Corp. (TSXV:TELO) (OTCQB: TDSGF) has revealed encouraging interim findings from its ongoing clinical trial assessing a telomere-based diagnostic platform designed to predict relapse risk in multiple myeloma patients. Conducted in partnership with the National and Kapodistrian University of Athens, the study identified a telomere-related nuclear architecture metric that achieved an Area Under the Curve (AUC) of 0.849 in distinguishing patients who relapsed from those who remained in remission. These results indicate that the company’s platform could provide a unique precision-medicine solution by integrating disease detection, relapse-risk prediction, and disease monitoring into a single blood-based assay, potentially filling a significant gap in current minimal residual disease (MRD) testing methods.
Key Highlights
- Telo Genomics Corp. (TSXV:TELO) reported interim outcomes from a retrospective clinical study involving 50 multiple myeloma patients, conducted with the National and Kapodistrian University of Athens.
- The study identified "Average Distance to Nuclear Center," a telomere-associated nuclear architecture parameter, as the most accurate predictor of relapse status, achieving an AUC of 0.849, indicating strong clinical diagnostic potential.
- The clinical trial is projected to complete by summer 2026; additional collaborations with Cleveland Clinic and Montreal Jewish General Hospital aim to assess MRD in roughly 20 multiple myeloma patients.
- Telo Genomics plans to continue validating its technology against existing standards of care, with expanded validation efforts anticipated through the end of 2026.
Study Design and Patient Cohort Details
The interim evaluation analyzed diagnostic blood samples from 50 multiple myeloma patients with comprehensive follow-up data, as per the company’s announcement. The cohort was carefully selected to include patients with known two-year clinical outcomes, facilitating direct comparisons between those who relapsed and those who stayed in remission. This retrospective approach enabled researchers to determine whether telomere-based parameters could effectively differentiate these patient groups.
The trial, conducted in collaboration with the National and Kapodistrian University of Athens, is expected to conclude in summer 2026. Utilizing baseline blood samples from patients treated under standard-of-care regimens underscores the company’s aim to develop a practical, non-invasive diagnostic tool suited for real-world clinical application.
Telomere Nuclear Architecture as a Predictor of Relapse
The interim findings highlighted "Average Distance to Nuclear Center," a telomere-associated nuclear architecture parameter linked to genomic instability, as the strongest predictor of relapse. Receiver Operating Characteristic (ROC) analysis demonstrated robust discrimination, with the assay achieving an AUC of 0.849. In clinical diagnostics, this level of AUC is considered highly predictive, underscoring the platform’s capacity to stratify patients by relapse risk effectively.
The announcement states that these interim results offer preliminary evidence supporting the Telo Genomics platform’s ability to provide liquid-biopsy-based prognostic data. The company emphasizes its three-dimensional telomere analysis method assesses genomic instability at the single-cell level, potentially delivering relapse-risk insights that complement existing MRD approaches such as EuroFlow next-generation flow cytometry and Adaptive Biotechnologies’ ClonoSEQ® assay.
Distinct Advantages Over Current MRD Technologies
The company notes that current MRD techniques, including Next-Generation Flow (NGF) and Next-Generation Sequencing (NGS), primarily quantify residual disease burden but do not evaluate biological factors driving relapse. Telo Genomics’ platform uniquely combines sensitive circulating tumor cell (CTC) detection with single-cell 3D telomere profiling to assess genomic instability and biological behavior of residual tumor cells.
According to the release, no clinically implemented MRD scoring system currently integrates residual disease detection with single-cell genomic instability profiling to predict relapse risk as Telo Genomics proposes. This integrated approach—encompassing disease detection, relapse-risk prediction, and disease progression monitoring within a single genomic instability-based assay—addresses a critical limitation of existing MRD technologies and may enable more personalized treatment strategies.
Clinical and Technological Capabilities Demonstrated
The interim data reveal several key clinical and technological strengths of the Telo Genomics platform. These include the potential for telomere-driven nuclear architecture patterns to serve as predictive biomarkers of relapse risk, the ability to detect biologically aggressive disease not identified by conventional residual disease measures, and the capability to merge residual disease detection with relapse-risk stratification in one test.
Additional advantages highlighted include the potential for serial 3D telomere profiling to monitor disease evolution over time and the use of blood-based testing to reduce reliance on invasive bone marrow biopsies. The company suggests these features could support critical treatment decisions and enhance the management of multiple myeloma patients.
Ongoing Validation at Cleveland Clinic and Montreal Jewish General Hospital
Telo Genomics has established partnerships with Cleveland Clinic and Montreal Jewish General Hospital to conduct further clinical studies analyzing MRD in approximately 20 multiple myeloma patients. These studies involve blood and bone marrow samples collected at various treatment stages. The company previously demonstrated an analytical detection limit of one tumor cell per 10 million white blood cells, as published in BioTechniques.
The current research aims to directly compare Telo Genomics’ ability to isolate and characterize circulating tumor cells from peripheral blood against NGS-based MRD outcomes from Adaptive Biotechnologies’ ClonoSEQ®, a leading NGS MRD platform. The study also incorporates serial 3D telomere profiling to longitudinally track both MRD status and genomic instability, enabling correlation of telomere architecture changes with disease progression, treatment response, and clinical outcomes.
Executive Insights on Clinical Impact
John Farlinger, CEO and Chairman of Telo Genomics, commented, "These interim results reinforce our conviction that telomere-driven genomic instability analysis could offer clinicians a novel method to assess relapse risk in multiple myeloma." He noted that while current monitoring tools effectively measure disease burden, they fall short in identifying patients at highest relapse risk. Farlinger expressed optimism that the company’s platform may fill this critical gap, representing a significant opportunity not only in multiple myeloma but also across other cancers and Alzheimer’s disease.
Dr. Sabine Mai, Co-Founder and Director of Telo Genomics, added, "These findings provide preliminary evidence that our platform can deliver liquid-biopsy-based prognostic information." She emphasized that current MRD methods, while valuable for residual disease quantification, do not evaluate biological factors driving relapse. Dr. Mai highlighted that by analyzing genomic instability through 3D telomere organization at the single-cell level, the platform offers prognostic insights that complement existing MRD techniques.
Validation Timeline and Comparative Analysis Plans
Telo Genomics plans to continue validating its technology against current standards of care, including direct comparisons with EuroFlow, Adaptive Biotechnologies, and other established MRD methodologies. These broader validation efforts are expected to extend through the end of 2026, underscoring the company’s commitment to firmly establish the clinical utility and competitive advantage of its platform within the MRD diagnostic landscape.
The emphasis on head-to-head comparisons with leading platforms reflects the company’s dedication to demonstrating the incremental value of its telomere-based approach, a critical step for regulatory approval, clinical adoption, and reimbursement in the diagnostic market.
Company Overview and Technology Platform
Telo Genomics is a biotechnology firm pioneering a comprehensive telomere platform with prognostic applications in liquid biopsies and related oncology and neurological disease technologies. The company integrates quantitative 3D telomere analysis with molecular biology and artificial intelligence to detect disease-associated genetic instability.
The company’s proprietary technology benefits are supported by over 190 peer-reviewed publications and more than 30 clinical studies involving upwards of 3,000 patients with various cancers and Alzheimer’s disease. Its lead application, Telo-MM, is being developed to provide actionable insights for clinicians treating multiple myeloma, a blood cancer.
